Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai/UCL’s Anti-Tau Antibody Heading into PI for Alzheimer’s Disease
Eisai and its partner University College London said on December 6 that they have started preparing for PI Alzheimer’s studies on E2814, the first clinical candidate from their drug discovery collaboration, hoping to launch the programs by the end of…
To read the full story
Related Article
- Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
- Eisai to Form Alliance with University College London for Drug Discovery Research
December 18, 2012
- Eisai, UCL to Collaborate in Neurodegenerative Disease
June 6, 2011
BUSINESS
- Shionogi Pivoting to Function-Based Model in Global HR Revamp
September 1, 2026
- SanBio to Move All Akuugo Manufacturing to Minaris’ Yokohama Site
September 1, 2026
- Merck KGaA to Consolidate Japan Life Science Labs at Haneda Hub
September 1, 2026
- FDA Approves Takeda’s PV Drug Mimrylo
September 1, 2026
- Sarclisa SC Can Meet Patient, Healthcare Worker Needs: Specialist
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…